Toggle SlidingBar Area

eigerbioadmin

»eigerbioadmin

About eigerbioadmin

This author has not yet filled in any details.
So far eigerbioadmin has created 82 blog entries.
18 09, 2017

Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors

2017-09-18T14:31:19+00:00

Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors - Company Advancing Multiple Programs in Orphan Disease Pipeline PALO ALTO, Calif., September 18, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of Evan Loh, MD to [...]

Eiger Announces Appointment of Biopharmaceutical Industry Veteran Evan Loh, MD to its Board of Directors 2017-09-18T14:31:19+00:00
5 09, 2017

Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

2017-09-05T13:52:48+00:00

Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection PALO ALTO, Calif., Sept 5, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan designation for pegylated [...]

Eiger Announces FDA Orphan Drug Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 2017-09-05T13:52:48+00:00
30 08, 2017

Eiger BioPharmaceuticals to Present at Two Upcoming Investor Conferences

2017-08-30T15:19:09+00:00

Eiger BioPharmaceuticals to Present at Two Upcoming Investor Conferences PALO ALTO, Calif. – August 30, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for orphan diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update at two upcoming meetings [...]

Eiger BioPharmaceuticals to Present at Two Upcoming Investor Conferences 2017-08-30T15:19:09+00:00
14 08, 2017

Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results

2017-08-14T19:09:14+00:00

Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results - Five Phase 2 Programs Advancing in Multiple Orphan Indications - Multiple Clinical and Regulatory Milestones Expected 2017-2018 PALO ALTO, Calif., August 14, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today financial results for [...]

Eiger BioPharmaceuticals Reports Second Quarter 2017 Financial Results 2017-08-14T19:09:14+00:00
8 08, 2017

Eiger BioPharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference on August 16th

2017-08-08T12:00:07+00:00

Eiger BioPharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference on August 16th PALO ALTO, Calif. – August 8, 2017 – Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of targeted therapies for rare diseases, announced today that David Cory, President and CEO of Eiger, will present a corporate overview and business update [...]

Eiger BioPharmaceuticals to Present at 2017 Wedbush PacGrow Healthcare Conference on August 16th 2017-08-08T12:00:07+00:00
27 07, 2017

Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

2017-07-27T15:06:44+00:00

Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection PALO ALTO, Calif., July 27, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for [...]

Eiger Announces FDA Fast Track Designation Granted for Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 2017-07-27T15:06:44+00:00
24 07, 2017

Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection

2017-07-24T12:02:26+00:00

Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection LIMT HDV: Lambda Interferon MonoTherapy in HDV Study PALO ALTO, Calif., July 24, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq: EIGR), focused on the development and commercialization of targeted therapies for rare diseases, today announced completion of enrollment [...]

Eiger Completes Enrollment in Phase 2 LIMT HDV Study of Pegylated Interferon Lambda in Hepatitis Delta Virus Infection 2017-07-24T12:02:26+00:00
29 06, 2017

Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals

2017-06-30T18:22:25+00:00

Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals PALO ALTO and SAN DIEGO, Calif., June 29, 2017, Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), announced today an agreement to sell to Theragene Pharmaceuticals, Inc., a private biotechnology company, a non-strategic asset, Mydicar® (rAAV1-SERCA2a).  Financial terms of the agreement include a total upfront of $3.1 million in [...]

Eiger BioPharmaceuticals Announces Sale of Non-Strategic Assets to Theragene Pharmaceuticals 2017-06-30T18:22:25+00:00
14 06, 2017

Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors

2017-06-14T16:56:31+00:00

Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors - Company Prepares to Advance Orphan Disease Pipeline PALO ALTO, Calif., June 14, 2017 -- Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for rare diseases, announced today the appointment of David Apelian, MD, [...]

Eiger Announces Appointment of Biopharmaceutical Industry Veteran David Apelian, MD, PhD, MBA to its Board of Directors 2017-06-14T16:56:31+00:00
12 06, 2017

Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego

2017-06-12T14:46:00+00:00

Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego - Novel Liquid Formulation of Subcutaneous Exendin 9-39 Highlighted PALO ALTO, Calif., June 12, 2017 — Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), focused on the development and commercialization of therapies for [...]

Eiger Reports Additional Positive Phase 2 Results from Multiple-Ascending Dose Study of Exendin 9-39 in Post-Bariatric Hypoglycemia Patients at American Diabetes Association Meeting in San Diego 2017-06-12T14:46:00+00:00

About Us

EigerBio Logo

We are a values-driven company that works to embody Integrity, Passion, Accountability, Creativity, and Teamwork in the pursuit of our mission.

Privacy Policy | Terms & Conditions

Therapeutic Areas

Hepatitis Delta
Post-bariatric Hypoglycemia
Pulmonary Arterial Hypertension
Lymphedema
Home
About Eiger
Pipeline
News
Investors
Careers
Contact Us

Contact

Eiger BioPharmaceuticals, Inc.
350 Cambridge Ave, Suite 350
Palo Alto, CA  94306

Phone: 1-877-899-2051
Fax: 650-618-1621
Email: info@eigerbio.com

Click Here for Directions

Eiger BioPharmaceuticals © 2017 | All Rights Reserved